Halozyme Therapeutics (HALO) Deferred Taxes (2012 - 2026)
Halozyme Therapeutics (HALO) reported Deferred Taxes of -$3.4 million for Q1 2026, down 219.94% year-over-year from $2.9 million in Q1 2025, and down 120.44% quarter-over-quarter from $16.8 million in Q4 2025.
Halozyme Therapeutics (HALO) Deferred Taxes (2012 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 10 years of Deferred Taxes data on file, last reported at -$3.4 million in Q1 2026.
- Deferred Taxes for Q1 2026 came in at -$3.4 million, down 219.94% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.9 million (down 291.32% YoY), and the FY2025 annual result was -$634000.0, down 19.17% from the prior year.
- Deferred Taxes slipped to -$3.4 million in Q1 2026 per HALO's latest filing, from $16.8 million in the prior quarter.
- Over five years, Deferred Taxes peaked at $16.8 million in Q4 2025 and troughed at -$27.4 million in Q3 2025.
- A 5-year average of -$4.7 million and a median of -$3.9 million in 2023 frame the typical range for Deferred Taxes.
- On a YoY basis, Deferred Taxes climbed as much as 321.38% in 2025 and fell as far as 9267.81% in 2025.
- A 5-year view of Deferred Taxes shows it stood at -$14.7 million in 2022, then soared by 35.79% to -$9.4 million in 2023, then jumped by 262.28% to $15.3 million in 2024, then advanced by 9.65% to $16.8 million in 2025, then plunged by 120.44% to -$3.4 million in 2026.
- Business Quant data shows HALO's Deferred Taxes at -$3.4 million in Q1 2026, $16.8 million in Q4 2025, and -$27.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -859,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -65.30 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn | -3.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.43 Mn |
| Dec 31, 2025 | 16.77 Mn |
| Sep 30, 2025 | -27.35 Mn |
| Jun 30, 2025 | 7.09 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 15.29 Mn |
| Sep 30, 2024 | -292,000.00 |
| Jun 30, 2024 | -14.24 Mn |
| Mar 31, 2024 | -1.29 Mn |
| Dec 31, 2023 | -9.42 Mn |
| Sep 30, 2023 | -9.70 Mn |
| Jun 30, 2023 | -11.51 Mn |
| Mar 31, 2023 | -3.87 Mn |
| Dec 31, 2022 | -14.68 Mn |
| Sep 30, 2022 | -25.70 Mn |
| Jun 30, 2022 | 13.30 Mn |
| Mar 31, 2022 | -12.93 Mn |
| Dec 31, 2021 | 12.95 Mn |
| Sep 30, 2021 | 142.48 Mn |
| Jun 30, 2015 | -63,000.00 |